New gene therapy shows promise for treating fusion-driven cancers

A new study presents a promising treatment method for so-called fusion-driven cancers, which are currently often difficult to cure. These fusion-driven cancers are caused by an error in cell division that creates a fusion of different genes.

Are COVID-19 outcomes, including severe COVID-19 and persistent symptoms, associated with economic hardship among US families?

Researchers investigated the relationship between COVID-19 health outcomes, economic hardship during the pandemic, and pre-pandemic socioeconomic status in United States families.

December 13, 2023

Janssen seeks EMA approval for RYBREVANT in NSCLC

Share this article The Rybrevant regimen is intended for treating advanced non-small cell lung cancer. Credit: Minerva Studio / Shutterstock.com. The Janssen Pharmaceutical Companies of

February 9, 2024

In bid to save cash, Grail says it will cut 350 jobs and focus on multi-cancer test

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.